Valuation: Daxor Corporation

Market Cap 6.68Cr 5.83Cr 5.5Cr 5Cr 9.36Cr 641.44Cr 9.4Cr 66Cr 25Cr 326.12Cr 25Cr 25Cr 1.05TCr P/E 2026 *
-54.5x
P/E 2027 * -382x
Enterprise Value 6.68Cr 5.83Cr 5.5Cr 5Cr 9.36Cr 641.44Cr 9.4Cr 66Cr 25Cr 326.12Cr 25Cr 25Cr 1.05TCr EV / Sales 2026 *
7.19x
EV / Sales 2027 * 4.08x
Free-Float
46.7%
Yield 2026 *
-
Yield 2027 * -
1 week-0.17%
Current month+13.60%
1 month+11.27%
3 months+17.44%
6 months+3.06%
Current year-22.37%
1 week 10.56
Extreme 10.555
12.25
1 month 9.55
Extreme 9.5501
12.25
3 years 6.55
Extreme 6.55
14.76
5 years 6.55
Extreme 6.55
14.76
10 years 3.4
Extreme 3.4001
24.08
Manager TitleAgeSince
Chief Executive Officer 56 01/01/2013
Director of Finance/CFO 69 28/09/2018
Chief Tech/Sci/R&D Officer - 05/06/2024
Director TitleAgeSince
Director/Board Member 91 01/01/1989
Chairman 56 14/02/2017
Director/Board Member 70 22/06/2016
Change 5-day change 1-year change 3-year change Capi.($)
-1.55%-0.17%+0.44%+22.20% 6.79Cr
+0.67%+0.52%+17.92%+119.32% 1.59TCr
+2.31%+3.63%+53.00%+175.16% 1.29TCr
-0.11%-3.38%-23.07%+21.90% 852.97Cr
+0.97%+1.09%+31.03%+146.17% 775.12Cr
-2.06%-0.93%+3.62%+18.90% 668.29Cr
-1.44%-2.37%-27.07%-18.12% 674.81Cr
+0.13%+1.42%+11.63%+29.02% 483.98Cr
-1.27%-4.54%+1.41%+0.80% 385.11Cr
+0.80%+1.07% - - 385.9Cr
Average -0.00%-0.43%+7.66%+57.26% 789.62Cr
Weighted average by Cap. +0.31%-0.20%+13.61%+83.63%

Financials

2026 *2027 *
Net sales 93L 81.1L 76.57L 69.53L 1.3Cr 89Cr 1.31Cr 9.17Cr 3.54Cr 45Cr 3.49Cr 3.42Cr 145.98Cr 1.64Cr 1.43Cr 1.35Cr 1.23Cr 2.3Cr 157.37Cr 2.31Cr 16Cr 6.24Cr 80Cr 6.16Cr 6.02Cr 257.43Cr
Net income -12L -10.46L -10L -9L -16.81L -12Cr -16.88L -1.18Cr -45.67L -5.85Cr -45.08L -44.08L -19Cr -2L -2L -2L -1L -3L -1.92Cr -3L -19.73L -8L -97.57L -8L -7L -3.14Cr
Net Debt - -
Logo Daxor Corporation
Daxor Corporation is a diversified, closed-end management investment company. Its focus and operations are as a medical device manufacturing, company. It specializes in blood volume measurement technology focused on blood volume testing innovation. It markets the Blood Volume Analyzer (BVA)-100, the diagnostic blood test cleared by the FDA to provide objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000 tests have been performed at hospital centers across the United States, enhancing hospital performance metrics in a range of surgical and medical conditions, including reducing mortality and readmissions in heart failure and critical care. Its facility provides on-demand, next day blood volume analysis results. It has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the United States Department of Defense.
Employees
-
Date Price Change Volume
18/26/18 $11.45 -1.55% 26,884
17/26/17 $11.63 -0.73% 31,103
16/26/16 $11.72 +5.07% 2,01,091
15/26/15 $11.15 -1.03% 15,848
14/26/14 $11.27 -1.78% 2,00,675
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
11.45USD
Average target price
20.00USD
Spread / Average Target
+74.67%

Quarterly revenue - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!